Responsiveness of human retinoblastoma and neuroblastoma models to a non-calcemic 19-nor Vitamin D analog

Daniel Albert, Lori A. Plum, William Yang, Marcus Marcet, Mary J. Lindstrom, Margaret Clagett-Dame, Hector F. DeLuca

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objectives: To investigate the effectiveness of 2-methylene-19-nor-(20S)- 1α-hydroxybishomopregnacalciferol (2MbisP) in inhibiting the growth of retinoblastoma (RB) and neuroblastoma (NB). Methods: For the RB study, the xenograft athymic mouse/human retinoblastoma cell (Y-79) model and the transgenic β-luteinizing hormone-large T antigen (LHβ-Tag) mice were systemically treated with 2MbisP or vehicle for 5 weeks. For the NB study, the xenograft athymic mouse/human neuroblastoma cell (SK-N-AS) model was treated with 2MbisP or vehicle for 5 weeks. Tumor size and toxicity were assessed. Results: In the xenograft models of RB and NB, 2MbisP caused statistically significant inhibition of tumor growth. Tumor growth inhibition was also observed in the transgenic RB mice, but did not achieve statistical significance. In all the groups, no biologically significant toxic effects were observed using the following variables: serum calcium levels, degree of kidney calcification, changes in body weight or survival. Conclusions: In athymic mice, 2MbisP was effective in inhibiting RB and NB growth compared with controls. A lesser effect was seen in the transgenic RB model. 2MbisP did not cause hypercalcemia or a significant increase in mortality. Clinical relevance: 2MbisP should be considered for use in clinical trials of RB and NB.

Original languageEnglish (US)
Pages (from-to)165-172
Number of pages8
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume97
Issue number1-2
DOIs
StatePublished - Oct 1 2005
Externally publishedYes

Fingerprint

Retinoblastoma
Neuroblastoma
Vitamin D
Heterografts
Tumors
Nude Mice
Growth
Poisons
Viral Tumor Antigens
Neoplasms
Body Weight Changes
Luteinizing Hormone
2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol
Hypercalcemia
Toxicity
Transgenic Mice
Calcium
Clinical Trials
Kidney
Survival

Keywords

  • Hypercalcemia
  • Neuroblastoma
  • Retinoblastoma
  • Tumor inhibition
  • Vitamin D analog

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Endocrinology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Responsiveness of human retinoblastoma and neuroblastoma models to a non-calcemic 19-nor Vitamin D analog. / Albert, Daniel; Plum, Lori A.; Yang, William; Marcet, Marcus; Lindstrom, Mary J.; Clagett-Dame, Margaret; DeLuca, Hector F.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 97, No. 1-2, 01.10.2005, p. 165-172.

Research output: Contribution to journalArticle

Albert, Daniel ; Plum, Lori A. ; Yang, William ; Marcet, Marcus ; Lindstrom, Mary J. ; Clagett-Dame, Margaret ; DeLuca, Hector F. / Responsiveness of human retinoblastoma and neuroblastoma models to a non-calcemic 19-nor Vitamin D analog. In: Journal of Steroid Biochemistry and Molecular Biology. 2005 ; Vol. 97, No. 1-2. pp. 165-172.
@article{48560b8588f7409f9da08e2eb451b58a,
title = "Responsiveness of human retinoblastoma and neuroblastoma models to a non-calcemic 19-nor Vitamin D analog",
abstract = "Objectives: To investigate the effectiveness of 2-methylene-19-nor-(20S)- 1α-hydroxybishomopregnacalciferol (2MbisP) in inhibiting the growth of retinoblastoma (RB) and neuroblastoma (NB). Methods: For the RB study, the xenograft athymic mouse/human retinoblastoma cell (Y-79) model and the transgenic β-luteinizing hormone-large T antigen (LHβ-Tag) mice were systemically treated with 2MbisP or vehicle for 5 weeks. For the NB study, the xenograft athymic mouse/human neuroblastoma cell (SK-N-AS) model was treated with 2MbisP or vehicle for 5 weeks. Tumor size and toxicity were assessed. Results: In the xenograft models of RB and NB, 2MbisP caused statistically significant inhibition of tumor growth. Tumor growth inhibition was also observed in the transgenic RB mice, but did not achieve statistical significance. In all the groups, no biologically significant toxic effects were observed using the following variables: serum calcium levels, degree of kidney calcification, changes in body weight or survival. Conclusions: In athymic mice, 2MbisP was effective in inhibiting RB and NB growth compared with controls. A lesser effect was seen in the transgenic RB model. 2MbisP did not cause hypercalcemia or a significant increase in mortality. Clinical relevance: 2MbisP should be considered for use in clinical trials of RB and NB.",
keywords = "Hypercalcemia, Neuroblastoma, Retinoblastoma, Tumor inhibition, Vitamin D analog",
author = "Daniel Albert and Plum, {Lori A.} and William Yang and Marcus Marcet and Lindstrom, {Mary J.} and Margaret Clagett-Dame and DeLuca, {Hector F.}",
year = "2005",
month = "10",
day = "1",
doi = "10.1016/j.jsbmb.2005.06.019",
language = "English (US)",
volume = "97",
pages = "165--172",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "1-2",

}

TY - JOUR

T1 - Responsiveness of human retinoblastoma and neuroblastoma models to a non-calcemic 19-nor Vitamin D analog

AU - Albert, Daniel

AU - Plum, Lori A.

AU - Yang, William

AU - Marcet, Marcus

AU - Lindstrom, Mary J.

AU - Clagett-Dame, Margaret

AU - DeLuca, Hector F.

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Objectives: To investigate the effectiveness of 2-methylene-19-nor-(20S)- 1α-hydroxybishomopregnacalciferol (2MbisP) in inhibiting the growth of retinoblastoma (RB) and neuroblastoma (NB). Methods: For the RB study, the xenograft athymic mouse/human retinoblastoma cell (Y-79) model and the transgenic β-luteinizing hormone-large T antigen (LHβ-Tag) mice were systemically treated with 2MbisP or vehicle for 5 weeks. For the NB study, the xenograft athymic mouse/human neuroblastoma cell (SK-N-AS) model was treated with 2MbisP or vehicle for 5 weeks. Tumor size and toxicity were assessed. Results: In the xenograft models of RB and NB, 2MbisP caused statistically significant inhibition of tumor growth. Tumor growth inhibition was also observed in the transgenic RB mice, but did not achieve statistical significance. In all the groups, no biologically significant toxic effects were observed using the following variables: serum calcium levels, degree of kidney calcification, changes in body weight or survival. Conclusions: In athymic mice, 2MbisP was effective in inhibiting RB and NB growth compared with controls. A lesser effect was seen in the transgenic RB model. 2MbisP did not cause hypercalcemia or a significant increase in mortality. Clinical relevance: 2MbisP should be considered for use in clinical trials of RB and NB.

AB - Objectives: To investigate the effectiveness of 2-methylene-19-nor-(20S)- 1α-hydroxybishomopregnacalciferol (2MbisP) in inhibiting the growth of retinoblastoma (RB) and neuroblastoma (NB). Methods: For the RB study, the xenograft athymic mouse/human retinoblastoma cell (Y-79) model and the transgenic β-luteinizing hormone-large T antigen (LHβ-Tag) mice were systemically treated with 2MbisP or vehicle for 5 weeks. For the NB study, the xenograft athymic mouse/human neuroblastoma cell (SK-N-AS) model was treated with 2MbisP or vehicle for 5 weeks. Tumor size and toxicity were assessed. Results: In the xenograft models of RB and NB, 2MbisP caused statistically significant inhibition of tumor growth. Tumor growth inhibition was also observed in the transgenic RB mice, but did not achieve statistical significance. In all the groups, no biologically significant toxic effects were observed using the following variables: serum calcium levels, degree of kidney calcification, changes in body weight or survival. Conclusions: In athymic mice, 2MbisP was effective in inhibiting RB and NB growth compared with controls. A lesser effect was seen in the transgenic RB model. 2MbisP did not cause hypercalcemia or a significant increase in mortality. Clinical relevance: 2MbisP should be considered for use in clinical trials of RB and NB.

KW - Hypercalcemia

KW - Neuroblastoma

KW - Retinoblastoma

KW - Tumor inhibition

KW - Vitamin D analog

UR - http://www.scopus.com/inward/record.url?scp=27544478276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27544478276&partnerID=8YFLogxK

U2 - 10.1016/j.jsbmb.2005.06.019

DO - 10.1016/j.jsbmb.2005.06.019

M3 - Article

C2 - 16055326

AN - SCOPUS:27544478276

VL - 97

SP - 165

EP - 172

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 1-2

ER -